Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2023 Dec 18;27(2):62. doi: 10.3892/ol.2023.14193

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright: © Inoue et al.

This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.

PMC Copyright notice

Figure 2. — Prognostic impact of the transfusion units required within 28 days from the start of AZA with PC28. (A) CS-AZA1, (B) CLFS-AZA-1 and (C) cumulative incidence of progression to AML based on severe thrombocytopenia defined by PC28 or not. The causes of death in patients with (D) severe thrombocytopenia and (E) those without who died within the follow-up period. CS-AZA1, conditional survival period after the first cycle of azacitidine treatment; CLFS-AZA1, conditional leukemia-free survival period after the first cycle of azacitidine treatment; AML, acute myeloid leukemia; PC28, platelet concentrate transfusion units required within 28 days from the start of AZA.